Company Profile: Sequenom, Inc.-Reference-Cited by-同舟云学术

Company Profile: Sequenom, Inc.

Published:2012-04 Issue:5 Volume:13 Page:529-531
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Cantor Charles R¹

Affiliation:

1. Sequenom, Inc., 3595 John Hopkins Ct, San Diego, CA 92121, USA.

Abstract

There is broad acceptance in both the research and clinical communities that the age of personalized medicine is rapidly approaching. Numerous examples of biomarkers (and tests based on those biomarkers) have been shown to be relevant to clinically important phenotypes. Sequenom, Inc. is at the forefront of this molecular medicine revolution. The company provides genetic analysis instrumentation and reagents to the clinical and research communities. These products are being used for clinical validation of relevant biomarkers as well as for development of diagnostic tests based on those biomarkers.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.12.8

Reference4 articles.

1. Gene and drug matrix for personalized cancer therapy

2. Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

3. The largest prospective warfarin-treated cohort supports genetic forecasting

4. Sensitive Detection of BCR-ABL1 Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An effective method based on real time fluorescence quenching for single nucleotide polymorphism detection;Journal of Biotechnology;2014-09

2. Matrix-Assisted Laser Desorption/Ionisation, Time-of-Flight Mass Spectrometry–Based Blood Group Genotyping—The Alternative Approach;Transfusion Medicine Reviews;2013-01

3. The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics;Clinical Pharmacology & Therapeutics;2012-08-29